Case Reports: Practical Use of Pulmonary Inhaled (Technosphere) Insulin in Type 1 Diabetes, Type 2 Diabetes, and Pregnancy

Limitations in current insulin formulations contribute to suboptimal glycemic control and increased risks of hypoglycemia and hyperglycemia. Afrezza® with Technosphere® inhaled insulin (TI) offers a novel therapeutic option with a rapid pharmacokinetic and pharmacodynamic profile, addressing challenges associated with injectable insulin therapies. This article presents case reports that illustrate the clinical applications of TI across diverse patient populations, including type 1 diabetes, type 2 diabetes (T2D), pregnancy complicated by T2D, and exercise-related glycemic management.